CHOSA enters into an agreement with a CLIA-certified laboratory partner for Platin-DRP® in the USA - first revenue expected summer 2027

(FSE:W5L) CHOSA Oncology AB has entered into an agreement with a CLIA-certified laboratory to develop and validate Platin-DRP® as a laboratory-developed test (LDT) for US commercialization. The company expects first revenues from Platin-DRP® testing in the United States in summer 2027, contingent on successful analytical validation and implementation under the laboratory's CLIA certification. The CLIA programme builds on clinical results from CHOSA's collaboration with ETOP and EORTC, specifically the randomized Phase III SPLENDOUR trial, which included 82 patients with advanced NSCLC treated with cisplatin or carboplatin. Results presented at the European Lung Cancer Congress in March 2026 showed that patients with high Platin-DRP® scores had a median overall survival of 16.9 months, compared to 5.5 months for those with low scores. The company estimates the US market potential at more than 250,000 Platin-DRP® tests per year and expects to sell 300-500 tests in the first year. In a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery, patients with the 10% highest Platin-DRP® scores had a 3-year survival of 90%, while those with the lowest 10% scores had a 3-year survival of only 40%. CHOSA is also conducting a retrospective study with Mount Sinai Hospital in New York to evaluate Platin-DRP® in patients with advanced NSCLC treated with platinum chemotherapy combined with PD-1/PD-L1 immunotherapy, using 94 tumour biopsy samples from US patients. An initial read-out from this study is expected in the first quarter of 2027. Platin-DRP® is a gene expression-based biomarker designed to predict response to platinum-based chemotherapy, and CHOSA holds worldwide rights to the test. The company intends to enter into partnership or sublicensing agreements for LiPlaCis® and the DRP®. DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd and LiPlasome Pharma ApS. Peter Buhl Jensen is the CEO of CHOSA Oncology AB.

(FSE:W5L) CHOSA Oncology AB has entered into an agreement with a CLIA-certified laboratory to develop and validate Platin-DRP® as a laboratory-developed test (LDT) for US commercialization. The company expects first revenues from Platin-DRP® testing in the United States in summer 2027, contingent on successful analytical validation and implementation under the laboratory's CLIA certification. The CLIA-certified laboratory will provide development, validation, and related laboratory services to prepare Platin-DRP® for clinical use, establishing and documenting the test's analytical performance and implementing required laboratory procedures and quality controls. CHOSA estimates the US market potential at more than 250,000 Platin-DRP® tests per year and expects to sell 300-500 tests in the first year. The CLIA program builds on clinical results from CHOSA's collaboration with ETOP and EORTC, including analysis of 82 patients with advanced NSCLC treated with cisplatin or carboplatin in the randomized Phase III SPLENDOUR trial. Results presented at the European Lung Cancer Congress in March 2026 showed statistically significant associations between higher Platin-DRP® scores and longer progression-free and overall survival, with median overall survival of 16.9 months in the high-score group compared to 5.5 months in the low-score group. In a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery, patients with the 10% highest Platin-DRP® scores had a 3-year survival of 90%, while those with the lowest 10% scores had a 3-year survival of 40%. In parallel, CHOSA is conducting a retrospective study with Mount Sinai Hospital in New York to evaluate Platin-DRP® in patients with advanced NSCLC treated with platinum chemotherapy combined with PD-1/PD-L1 immunotherapy, using 94 tumour biopsy samples from US patients. An initial read-out from this study is expected in the first quarter of 2027. Platin-DRP® is a gene expression-based biomarker designed to predict response to platinum-based chemotherapy, and CHOSA holds worldwide rights to the test. DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (formerly Oncology Venture ApS) and LiPlasome Pharma ApS. Peter Buhl Jensen is CEO of CHOSA Oncology AB.